NLS Pharmaceutics AG (NLSP)

$0.7473

+0.04 (+5.25%)
Rating:
Recommendation:
-
Symbol NLSP
Price $0.7473
Beta 0.000
Volume Avg. 0.54M
Market Cap 15.639M
Shares () -
52 Week Range 0.33-2.83
1y Target Est -
DCF Unlevered NLSP DCF ->
DCF Levered NLSP LDCF ->
ROE 183.82% Strong Buy
ROA -91.89% Strong Sell
Operating Margin -
Debt / Equity 962.84% Strong Buy
P/E -
P/B 14.60 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest NLSP news


Healthcare
Biotechnology
NASDAQ Capital Market

NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company was incorporated in 2015 and is based in Zurich, Switzerland.